2018-04-01
Erratum to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy (PharmacoEconomics, (2018), 36, 1, (91-103), 10.1007/s40273-017-0557-6)
Publication
Publication
PharmacoEconomics , Volume 36 - Issue 4 p. 505
In the print publication the data in Table 2, has been incorrectly published.
Page 95, Table 2, final row, second column: the mean Advanced treatment annual cost which
previously read 83,249
should read 8324
| Additional Metadata | |
|---|---|
| doi.org/10.1007/s40273-018-0634-5, hdl.handle.net/1765/105191 | |
| PharmacoEconomics | |
| Organisation | Institute for Medical Technology Assessment (iMTA) |
|
Ansaripour, A., Uyl-de Groot, C., & Redekop, K. (2018). Erratum to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy (PharmacoEconomics, (2018), 36, 1, (91-103), 10.1007/s40273-017-0557-6). PharmacoEconomics, 36(4). doi:10.1007/s40273-018-0634-5 |
|
